Almac has added epigenetics to its expanding drug discovery offering with a new bespoke histone production service.
The Northern-Irish firm has launched a custom synthesis and reagents service for focused on the production of histones, which are the proteins involved with the packaging and expression of DNA that are believed to play a role in the development of some diseases.
The idea is that drug discovery scientists involved in epigenetic research can examine the histones – which Almac claims are exact replicas of those found in nature - as potential targets for novel pharmaceutical products.
Almac has been expanding its drug discovery and analysis offering over the last few years. The firm launched its protein-kinase based Flexyte platform in 2010 , attracting the attention of Anglo-Swedish drugmaker AstraZeneca.